PALIHealthcare · BiotechnologyPALI Stock Forecast: Palisade Bio, Inc. Price Predictions for 2026-2027
The 9 Wall Street analysts covering Palisade Bio, Inc. hold a median 12-month price target of $8 — +312.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 1 Aug 2026 — in the lower half.
PALI stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Palisade Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (77): The shares have been drifting up relative to others.
Issuance (24): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Palisade Bio, Inc. — and when they’d sell — is the membership.
PALI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PALI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +312.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 July 2026 | Oppenheimer | Initiates | Outperform | $8.00 |
| 9 Apr 2026 | Wolfe Research | Initiates | Outperform | — |
| 9 Apr 2026 | Wolfe Research | Initiates | Outperform | $7.00 |
| 26 Mar 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 25 Feb 2026 | Stifel | Initiates | Buy | — |
| 9 Jan 2026 | B. Riley Securities | Initiates | Buy | — |
| 30 Dec 2025 | Clear Street | Initiates | Buy | — |
| 29 Dec 2025 | Piper Sandler | Initiates | Overweight | — |
| 13 May 2025 | Brookline Capital | Maintains | Buy | — |
| 20 Nov 2024 | Brookline Capital | Initiates | Buy | — |
| 13 Nov 2024 | Maxim Group | Maintains | Buy | — |
| 1 May 2024 | Maxim Group | Reiterates | Buy | — |
| 16 Apr 2024 | Maxim Group | Maintains | Buy | — |
| 17 Nov 2023 | Maxim Group | Upgrade | Buy | — |
| 16 May 2023 | Ladenburg Thalmann | Maintains | Buy | — |
| 30 Mar 2023 | Maxim Group | Upgrade | Buy | — |
| 19 Aug 2022 | Maxim Group | Downgrade | Hold | — |
| 2 Feb 2022 | Ladenburg Thalmann | Initiates | Buy | — |
| 31 Aug 2021 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PALI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Palisade Bio, Inc. (PALI) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 15.8×
- Price / sales
- —
- Price / book
- 2.5×
- EV / EBITDA
- −7.4×
Cheaper than 46% of US stocks
Cheaper than 39% of US stocks
Cheaper than 82% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −36.4%
- Return on assets
- −23.4%
- Dividend yield
- —
Higher than 25% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
PALI vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PALI appears on the weeks it earns a place.
Frequently asked questions about PALI stock
What is the PALI stock price forecast for 2026-2027?
The 9 Wall Street analysts covering Palisade Bio, Inc. have a median 12-month price target of $8, with estimates ranging from $5 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PALI stock a buy right now?
Of the 9 analysts covering Palisade Bio, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Palisade Bio, Inc. 47 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PALI?
As at 1 Aug 2026, Palisade Bio, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (77 of 100).
Will PALI stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts implies +312.4% from the last close, and Ticker Nerd's factor model ranks Palisade Bio, Inc. 47 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PALI stock forecast for 2030?
No analyst covering Palisade Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PALI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $25 over the next 12 months.
How has PALI stock performed over the past year?
Palisade Bio, Inc. returned +92.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Palisade Bio, Inc. do?
Palisade Bio Inc. is a clinical-stage biopharmaceutical company dedicated to advancing drug therapies aimed at improving the safety and efficacy of treatments for acute and chronic gastrointestinal complications.
About Palisade Bio, Inc.
Palisade Bio Inc. is a clinical-stage biopharmaceutical company dedicated to advancing drug therapies aimed at improving the safety and efficacy of treatments for acute and chronic gastrointestinal complications. Known for its targeted focus on enhancing surgical outcomes, Palisade Bio's primary asset is its lead investigational drug candidate, designed to mitigate intestinal permeability and reduce related post-operative complications. The company's research initiatives are significant in medical areas such as gastrointestinal diseases, underscoring its commitment to innovations that potentially benefit patient recovery and healthcare systems. By developing solutions that aim to improve patient quality of life during surgical recoveries, Palisade Bio plays a vital role in the biotechnology sector, particularly in gastrointestinal health. Headquartered in Carlsbad, California, the company's efforts contribute to the broader field of biopharmaceutical development, positioning it as a key player in addressing unmet medical needs.
CEO Mr. J. D. Finley · 14 employees · United States · https://www.palisadebio.com